Well Pharmaceutical (603351.SH): Zou Jianguo plans to reduce holdings by no more than 9,300 shares
On May 21, Ge Longhui Pharmaceutical (603351.SH) announced that Mr. Zou Jianguo plans to reduce his total holdings of the company's shares by no more than 9,300 shares within 6 months after 15 trading days from the date of disclosure of the announcement, that is, no more than 0.0069% of the company's total share capital, or 25% of the total number of shares directly held by the company.
Well Pharmaceutical (603351.SH) released 2023 annual results, with net profit of 112 million yuan, an increase of 18.07% over the previous year
According to Zhitong Finance App News, Weil Pharmaceutical (603351.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 1,156 million yuan, an increase of 4.03%; net profit attributable to shareholders of listed companies was 112 million yuan, up 18.07% year on year; net profit attributable to shareholders of listed companies deducted 110 million yuan from non-recurring profit and loss, up 19.56% year on year; basic earnings per share were 0.83 yuan/share. After review and approval at the 8th meeting of the 3rd board of directors of the company, the company plans to use the total share capital on the share registration date at the time of implementation of the equity distribution to all shareholders for every 10
Nanjing Well Pharmaceutical GroupLtd (SHSE:603351) Is Reinvesting At Lower Rates Of Return
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in c
Weir Pharmaceutical (603351.SH): Termination of issuance of convertible corporate bonds to unspecified targets and withdrawal of application documents
Gelonghui, January 31 | Well Pharmaceutical (603351.SH) announced that since the company applied for this distribution, the company and intermediaries have actively promoted related work. In view of factors such as changes in the current market environment and the company's own actual situation, after careful analysis, research and communication, the company decided to stop issuing convertible corporate bonds to unspecified targets and withdraw the relevant application documents.
[BT Financial Report Instantaneous Analysis] Weir Pharmaceutical's 2023 Three-Quarter Report: A Financial Perspective Behind Steady Growth
Nanjing Well Pharmaceutical Group Co., Ltd. (stock code: 603351) is an enterprise that has been deeply involved in the field of pharmaceutical excipients and synthetic lubricant base oil products for many years. The company relies on core technology to provide high-quality products for the pharmaceutical and lubricant industries. In the face of policy advancement, changes in market demand, and international competition, Weir Pharmaceutical continues to strengthen quality control, improve product quality and safety, and meet challenges. At the same time, the company responds positively to the national “double carbon” target, promotes the application and development of synthetic lubricants, and contributes to carbon reduction. In terms of assets and liabilities, as of the end of the third quarter of 2023, Weill Pharmaceutical's total capital
Well Pharmaceutical (603351.SH) released the first three quarter results, net profit of 78.2715 million yuan, a year-on-year decrease of 0.36%
Well Pharmaceutical (603351.SH) released its report for the third quarter of 2023. The company achieved operating income of 8 in the first three quarters...
Shen Jiusi, a shareholder of Weir Pharmaceutical (603351.SH), reduced his holdings of the company by a total of 268,500 shares
Weir Pharmaceutical (603351.SH) issued an announcement. As of the announcement date, the current holdings reduction plan period has expired, and shareholders are in the mood...
Will Pharmaceutical (603351.SH) released first-half results, with net profit of 53.3864 million yuan, a year-on-year decrease of 12.14%
Weir Pharmaceutical (603351.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
The Recent 9.9% Gain Must Have Brightened CEO Renrong Wu's Week, Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Most Bullish Insider
Key Insights Significant insider control over Nanjing Well Pharmaceutical GroupLtd implies vested interests in company growth 52% of the business is held by the top 5 shareholders Using data from
Will Pharmaceuticals (603351.SH): Ten minority shareholders plan to transfer their total shareholding of 13% of Xingwei Biotech's shares to the company
On July 28, GLONGWI | WELL PHARMACEUTICAL (603351.SH) announced that in order to protect the legitimate rights and interests of the company and shareholders and avoid potential transfer of benefits, ten minority shareholders, including Wu Renrong, Gao Zhengsong, Chen Xinguo, and Shen Jiu4, agreed to transfer their total ownership of 13% of Xingwei Biotech's shares to the company. Since none of the minority shareholders of Xingwei Biotech mentioned above made actual payments, it was determined through joint negotiations between the parties to the transaction that the share transfer consideration was zero yuan. The specific matters of the share transfer are to be agreed upon by the company and the transferor by signing a separate “Equity Transfer Agreement”.
Will Pharmaceutical (603351.SH) 2022 equity distribution: $0.28 per share, equity registration on June 7
According to the Zhitong Finance App, Will Pharmaceutical (603351.SH) issued an announcement that the company's 2022 annual equity distribution will be implemented: based on the company's total share capital before implementation of the plan, a cash dividend of 0.28 yuan per share (tax included) will be distributed. The equity registration date is June 7, 2023, and the exclusion (interest) date is June 8, 2023.
Shen Jiushi, the main shareholder of Well Pharmaceutical (603351.SH), reduced his holdings by 201,000 shares
According to the Zhitong Finance App, Will Pharmaceutical (603351.SH) announced that as of May 11, 2023, Shen Jiusi, a shareholder holding 5% or more of the company's shares, had reduced his holdings by 201,000 shares through centralized bidding transactions, and the amount had been reduced by more than half.
Will Pharmaceutical (603351.SH): Net profit in 2022 fell 6.26% year-on-year, and plans to distribute 2.80 yuan per 10
Glonghui, April 24, 丨Well Pharmaceutical (603351.SH) announced its 2022 annual report. Operating revenue was 1,111 million yuan, up 6.59% year on year, net profit of 95029 million yuan, down 6.26% year on year, after deducting non-net profit of 92.055 million yuan, down 6.56% year on year, basic earnings per share 0.72 yuan, and distributed a cash dividend of 2.80 yuan for every 10 shares to all shareholders.
Will Pharmaceutical (603351.SH) announced first-quarter results, net profit of 26.31 million yuan, down 4.43% year-on-year
According to the Zhitong Finance App, Will Pharmaceutical (603351.SH) revealed its report for the first quarter of 2023. The company achieved revenue of 246 million yuan in the first quarter, a year-on-year decrease of 15.19%. Net profit attributable to shareholders of listed companies was RMB 263.10,700, a year-on-year decrease of 4.43%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 26.2696 million yuan, a year-on-year decrease of 5.09%. Basic earnings per share were $0.20 per share.
Will Pharmaceutical (603351.SH): Executive Wang Fuqiu has reduced his holdings by a total of 50,000 shares and has completed the implementation of the holdings reduction
Glonghui, March 27, 丨 Well Pharmaceutical (603351.SH) announced that as of March 24, 2023, executive Wang Fuqiu has reduced his holdings by a total of 50,000 shares through centralized bidding transactions. Currently, he directly holds 150,000 shares of the company, accounting for about 0.1107% of the company's total share capital. The holdings reduction plan has been completed.
Will Pharmaceutical (603351.SH): Majority shareholder Shen Jiushi plans to reduce holdings by no more than 4010,000 shares
Glonghui, Feb. 16, 丨Well Pharmaceutical (603351.SH) announced that Shen Jiushi, the majority shareholder of the company, plans to reduce the company's shares by no more than 4010,000 shares through centralized bidding transactions within 6 months after 15 trading days from the date of disclosure of the announcement, that is, no more than 0.2953% of the company's total share capital, and no more than 25% of the total number of company shares held by him.
Will Pharmaceutical (603351.SH): Executive Zou Jianguo reduced his holdings by 12,500 shares
Glonghui, January 13, 丨Well Pharmaceutical (603351.SH) announced that as of January 12, 2023, company executive Zou Jianguo had reduced his holdings by 12,500 shares through centralized bidding transactions. Currently, he directly holds 37,500 shares of the company, accounting for about 0.0277% of the company's total share capital. The implementation of the holdings reduction plan has been completed.
Following Recent Decline, Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Top Shareholder CEO Renrong Wu Sees Holdings Value Drop by 12%
If you want to know who really controls Nanjing Well Pharmaceutical Group Co.,Ltd. (SHSE:603351), then you'll have to look at the makeup of its share registry. With 53% stake, individual insiders pos
Will Pharmaceutical (603351.SH) executives Wang Fuqiu and Zou Jianguo plan to reduce their holdings by no more than 62,500 shares
According to the Zhitong Finance App, Will Pharmaceutical (603351.SH) announced that company executives Wang Fuqiu and Zou Jianguo plan to reduce the company's shares, totaling no more than 62,500 shares.
Here's Why Nanjing Well Pharmaceutical GroupLtd (SHSE:603351) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
No Data